{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:17:35Z","timestamp":1784888255107,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40122-024-00658-7","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T14:03:39Z","timestamp":1729519419000},"page":"1659-1678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-3711","authenticated-orcid":false,"given":"Charly","family":"Gaul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Holle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirja","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Baufeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"11","key":"658_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBDH Collaborators","year":"2018","unstructured":"Collaborators GBDH. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954\u201376.","journal-title":"Lancet Neurol"},{"issue":"5","key":"658_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBDN Collaborators","year":"2019","unstructured":"Collaborators GBDN. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380.","journal-title":"Lancet Neurol"},{"issue":"2","key":"658_CR3","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022;163(2):e293\u2013309.","journal-title":"Pain"},{"issue":"Suppl 6","key":"658_CR4","first-page":"2","volume":"5","author":"M Porst","year":"2020","unstructured":"Porst M, Wengler A, Leddin J, Neuhauser H, Katsarava Z, von der Lippe E, et al. Migraine and tension-type headache in Germany. Prevalence and disease severity from the BURDEN 2020 Burden of Disease Study. J Health Monit. 2020;5(Suppl 6):2\u201324.","journal-title":"J Health Monit"},{"issue":"Suppl 1","key":"658_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R. Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache. 2018;58(Suppl 1):17\u201332.","journal-title":"Headache"},{"issue":"3","key":"658_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1526-4610.2007.01004.x","volume":"48","author":"JL Brandes","year":"2008","unstructured":"Brandes JL. The migraine cycle: patient burden of migraine during and between migraine attacks. Headache. 2008;48(3):430\u201341.","journal-title":"Headache"},{"key":"658_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.mayocp.2016.02.013","volume":"91","author":"DC Buse","year":"2016","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, et al. Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO study. Mayo Clin Proc. 2016;91:596\u2013611.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"658_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain. 2019;20(1):41.","journal-title":"J Headache Pain"},{"key":"658_CR9","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"3","key":"658_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301\u201315.","journal-title":"Cephalalgia"},{"issue":"4","key":"658_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644\u201355.","journal-title":"Headache"},{"issue":"1","key":"658_CR12","first-page":"22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22\u201333.","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"658_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"issue":"3","key":"658_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/head.14053","volume":"61","author":"AK Kawata","year":"2021","unstructured":"Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK, et al. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache. 2021;61(3):438\u201354.","journal-title":"Headache"},{"issue":"1","key":"658_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223\u201331.","journal-title":"J Pharmacol Exp Ther"},{"key":"658_CR16","unstructured":"European Medicines Agency. EMEA\/H\/C\/004447\u2014PSUSA\/00010699\/201911. AIMOVIG Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aimovig-epar-product-information_en.pdf. Accessed 20 July 2023."},{"issue":"22","key":"658_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123\u201332.","journal-title":"N Engl J Med"},{"issue":"6","key":"658_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334.","journal-title":"Lancet Neurol"},{"issue":"10161","key":"658_CR19","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280\u20137.","journal-title":"Lancet"},{"issue":"4","key":"658_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/head.14266","volume":"62","author":"SJ Tepper","year":"2022","unstructured":"Tepper SJ, Sheikh HU, Dougherty CO, Nahas SJ, Winner PK, Karanam AK, et al. Erenumab dosage for migraine prevention: an evidence-based narrative review with recommendations. Headache. 2022;62(4):420\u201335.","journal-title":"Headache"},{"issue":"9","key":"658_CR21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/head.13946","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB. Determining thresholds for meaningful change for the Headache Impact Test (HIT-6) Total and item-specific scores in chronic migraine. Headache. 2020;60(9):2003\u201313.","journal-title":"Headache"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-024-00658-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:13:34Z","timestamp":1730978014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-024-00658-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1007\/s40122-024-00658-7","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Charly Gaul received honoraria for consulting and lectures within the past 3\u00a0years from AbbVie, Lilly, Novartis Pharma, Hormosan Pharma, Gr\u00fcnenthal, Sanofi-Aventis, Lundbeck, Perfood, Vectura, Dr. Reddys, Pfizer, Chordate and TEVA. His research is supported by a grant from the German Research Foundation (DFG). He does not hold any stocks of pharmaceutical companies. Astrid Gendolla received honoraria for consulting and lectures within the past 3\u00a0years from AbbVie, Lilly, Novartis Pharma, Hormosan Pharma, Gr\u00fcnenthal, Lundbeck, Perfood, Pfizer and TEVA. Dagny Holle received honoraria for consulting and lectures within the past 3\u00a0years from AbbVie, Lilly, Novartis Pharma, Hormosan Pharma, Gr\u00fcnenthal, Lundbeck, and TEVA. Her research is supported by a grant from the German Research Foundation (DFG). She is co-founder of headachy. Hartmut G\u00f6bel received honoraria for consulting and lectures from Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin-Chemie, Bionorica, Bristol Myers Squibb, Eli Lilly, Fujisawa, GlaxoSmithKline, Gr\u00fcnenthal, Hermal, Hormosan, Ipsen-Pharma, Janssen-Cilag, Johnson & Johnson, KrewelMeuselbach, Klosterfrau, Lichtwer, Menarini Pharma, Merz Pharmaceuticals, Minster Pharmaceuticals, MSD, Novartis Pharma, Pfizer, Pharmacia, Sandoz, Schaper & Br\u00fcmmer, Schwarz-Pharma, Teva, Weber & Weber, SmithKline Beecham. Mirja Koch is an employee of Novartis AG. Caroline Baufeld is an employee of Novartis Pharma GmbH. Cordula Weiss was an employee of Novartis Pharma GmbH at the time of study, and is currently employed by Bayerische Chemieverb\u00e4nde, Munich, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of the Medical Association of Hessen on May 31, 2019. Written informed consent was obtained from all participants. This study adheres to the reporting guidelines outlined within the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}